These trials showed clinically important pharmacokinetic interactions [seven] characterised by a decrease while in the clearance on the anticancer drug and therefore enhanced publicity. The interpretation of subsequent period II and III scientific trials was challenging as it was impossible to administer the same dose of chemotherapy while in the e